0001493152-18-013747.txt : 20180926 0001493152-18-013747.hdr.sgml : 20180926 20180926152558 ACCESSION NUMBER: 0001493152-18-013747 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180924 FILED AS OF DATE: 20180926 DATE AS OF CHANGE: 20180926 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BERMAN ROBERT ANDREW CENTRAL INDEX KEY: 0001258360 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38325 FILM NUMBER: 181087842 MAIL ADDRESS: STREET 1: C/O ITUS CORPORATION STREET 2: 12100 WILSHIRE BOULEVARD, SUITE 1275 CITY: LOS ANGELES STATE: CA ZIP: 90025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Hancock Jaffe Laboratories, Inc. CENTRAL INDEX KEY: 0001661053 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330936180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 70 DOPPLER CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-261-2900 MAIL ADDRESS: STREET 1: 70 DOPPLER CITY: IRVINE STATE: CA ZIP: 92618 4 1 ownership.xml X0306 4 2018-09-24 0 0001661053 Hancock Jaffe Laboratories, Inc. HJLI 0001258360 BERMAN ROBERT ANDREW 70 DOPPLER IRVINE CA 92618 1 1 0 0 Chief Executive Officer Stock Option (Right to Buy) 4.99 2018-09-24 4 A 0 1080207 2.71 A 2028-09-24 Common Stock 1080207 1080207 D On September 24, 2018, the Board of Directors of the Company approved the grant of a ten-year option to purchase an aggregate of 1,080,207 shares of the Company's common stock at an exercise price of $4.99 per share (the "Option") to the reporting person, which Option was issued pursuant to the terms of that certain employment agreement, dated March 30, 2018 (the "Effective Date"), between the reporting person and the Company (the "Employment Agreement"). The grant of the Option was in fulfillment of the express terms of the previously agreed to Employment Agreement, which was filed as an exhibit to the Company's Form S-1/A with the Securities and Exchange Commission on April 16, 2018. The Employment Agreement provides that the reporting person is entitled to receive an equity grant of an option to purchase up to 6.5% of the Company's common stock outstanding on a fully diluted basis at the closing of the Company's initial public offering. The shares subject to the Option will vest over a period of 2 years, with 1/5th of the shares subject to the Option having vested on the Effective Date (the "Initial Vesting") and the remaining shares vesting in substantially equal monthly installments during the twenty-four (24) month period following the Effective Date and ending March 30, 2020 (as of the date of this report 396,076 shares subject to the Option, including the Initial Vesting, have vested). /s/ Robert Berman 2018-09-26